This webinar focuses on general information about the fees charged for eye injections, along with information about entitlements from Medicare.
About the presenter
Dilini Manthilaka graduated with her Bachelor of Science majoring in Vision Science in 2015 from the University of New South Wales. She then completed a Master of Public Health from the University of Sydney in 2017. She has been working with MDFA for more than two years as an education officer, providing non-clinical support to macular disease patients, family members, and carers within the macular disease community.
Dilini also has previous experience working with volunteers at the Cancer Council NSW offering training and support.
Correction at 12:43:
In March 2021, the Pharmaceutical Benefits Advisory Committee (PBAC) recommended Beovu for listing on the Pharmaceutical Benefits Scheme (PBS). The listing recommendation is for wet AMD patients who are non-responsive despite first line anti-VEGF treatment with other agents. Further steps in the process need to be completed before Beovu becomes available on the PBS. MDFA will advise once Beovu is available on the PBS.